CytomX Therapeutics, Inc. Common Stock CTMX
i
Market dataready · fetched 2026-11-11T13:59:25.869Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T12:48:50.344361298Z
FundamentalsSEC EDGAR · ready · as of 2026-09-30 · fetched 2026-11-11T13:59:25.458502+00:00
CytomX Therapeutics, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 1.34 | 748.7% | 66.9% | |||
| 25Δ | 1.55 | 717.1% | 61.9% | |||
| 30Δ | 1.76 | 685.6% | 56.9% | |||
| 35Δ | 1.98 | 654.0% | 51.9% | |||
| 40Δ | 2.30 | 109.3% | 18.9% | 2.19 | 622.5% | 46.9% |
| 45Δ | 2.19 | 97.5% | 13.5% | 2.40 | 590.9% | 41.9% |
| 50Δ | 2.07 | 85.7% | 8.1% | 2.61 | 559.3% | 36.8% |
| 55Δ | 2.82 | 527.8% | 31.8% | |||
| 60Δ | 3.03 | 496.2% | 26.8% | |||
| 65Δ | 3.24 | 464.7% | 21.8% | |||
| 70Δ | 3.45 | 433.1% | 16.8% | |||
| 75Δ | 3.66 | 401.6% | 11.8% | |||
| 80Δ | ||||||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 1.34
- IV
- 748.7%
- B/E move
- 66.9%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 1.55
- IV
- 717.1%
- B/E move
- 61.9%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 1.76
- IV
- 685.6%
- B/E move
- 56.9%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 1.98
- IV
- 654.0%
- B/E move
- 51.9%
40Δ
- Pseudo strike
- 2.30
- IV
- 109.3%
- B/E move
- 18.9%
- Pseudo strike
- 2.19
- IV
- 622.5%
- B/E move
- 46.9%
45Δ
- Pseudo strike
- 2.19
- IV
- 97.5%
- B/E move
- 13.5%
- Pseudo strike
- 2.40
- IV
- 590.9%
- B/E move
- 41.9%
50Δ
- Pseudo strike
- 2.07
- IV
- 85.7%
- B/E move
- 8.1%
- Pseudo strike
- 2.61
- IV
- 559.3%
- B/E move
- 36.8%
55Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 2.82
- IV
- 527.8%
- B/E move
- 31.8%
60Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.03
- IV
- 496.2%
- B/E move
- 26.8%
65Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.24
- IV
- 464.7%
- B/E move
- 21.8%
70Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.45
- IV
- 433.1%
- B/E move
- 16.8%
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.66
- IV
- 401.6%
- B/E move
- 11.8%
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 197.91% | |
| 170.69% | |
| 173.95% | |
| 186.53% | |
| 257.76% | |
| 217.28% | |
| 216.64% | |
| 230.21% | |
| 258.96% |
Biotechnology
CTNM
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation,…
More →CYTK
Cytokinetics, Incorporated, an advanced stage biopharmaceutical company, focuses on discovering, developing and commercializing muscle activators and inhibitors as potential…
More →DBVT
DBV Technologies SA, a clinical-stage biopharmaceutical company, is dedicated to the research and development of epicutaneous immunotherapy products. The company is headquartered…
More →DFTX
Definium Therapeutics, Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company is headquartered in New York, New…
More →DMAC
Description unavailable
More →DNA
Ginkgo Bioworks Holdings (DNA) is a pioneering force in synthetic biology, leveraging advanced genetic engineering to create customized bioengineered organisms suitable for a wide…
More →